Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
BMS ahead of the PD-1 oncology pack
BMS has announced EMA acceptance of its filing for PD-1 immune checkpoint inhibitor Opdivo while new cancer data flows in from the Euro Society for Medical Oncology meeting.
Approvals Action
Aspen moves on glaucoma market
Aspen has registered new competition for MSD Australia's Trusopt and Cosopt, while Mundipharma has won approval for new doses of painkiller Targin.
Special Report
Tim James' vision for Medicines Australia
Medicines Australia's new chief executive Tim James speaks to Pharma in Focus about how personal experience has shaped his view of industry where he believes he can make a difference.
Open Forum
When silence is leaden: the meaning of media avoidance
What do you think when a major corporate figure responds to the media with silence, declining to be interviewed? Is it signal of evasion, a conditioned response to regulatory curbs or just sensibly avoiding a hammering? Martin Palin weighs the inferences.
Working Life
Are you a slave to technology?
According to a recent survey conducted by Ipsos on behalf of Microsoft, 76 per cent of us use a smartphone and 45 per cent use a tablet. Does this mean technology is taking over our working and private lives?